FIRST HOPE FOR PEOPLE WITH FABRY DISEASE.
PR Newswire, London, March 28. This press release is transmitted on behalf of Transkaryotic Therapies Europe. Transkaryotic Therapies (TKT) Europe - 5S AB today announced that the Committee for Proprietary Medicinal Products (CPMP) of the European Agency for the Evaluation of Medicinal Products (EMEA) has...

NEW TREATMENT AVAILABLE FOR FABRY DISEASE IN EUROPE.
PR Newswire, London, August 3. This press release is transmitted on behalf of Transkaryotic Therapies. TKT receives European approval of Replagal for enzyme replacement therapy in Fabry disease Cambridge, Massachusetts - Transkaryotic Therapies, Inc. (Nasdaq: TKTX) today announced the European Commission has granted...

FIRST TREATMENT AVAILABLE FOR PEOPLE WITH DEBILITATING DISEASE.
First product granted a license under new EU orphan medicinal product legislation PR Newswire, London, August 3. This press release is transmitted on behalf of TKT Europe-5S AB. TKT Europe-5S AB today announced that Replagal(tm) (agalsidase alfa) has received full marketing authorisation in the EU...

FIRST HOPE FOR PEOPLE WITH FABRY DISEASE.
PR Newswire, London, March 28. This press release is transmitted on behalf of Transkaryotic Therapies Europe. Transkaryotic Therapies (TKT) Europe - 5S AB today announced that the Committee for Proprietary Medicinal Products (CPMP) of the European Agency for the Evaluation of Medicinal Products (EMEA) has...

TKT Announces Second Quarter 2001 Financial Results.
-- First Product Sales Reported -- CAMBRIDGE, Mass., July 31 /PRNewswire/ -- Transkaryotic Therapies, Inc. (Nasdaq: TKTX) reported today financial results for the three and six months ended June 30, 2001. For the three months ended June 30, 2001, TKT had a net loss of...

ViaCell, Inc., The World's Largest Umbilical Cord Blood Research and Banking Company Comments on Bush Administration's Decision.
Company supports the Administration's commitment to additional funding for alternative and promising stem cell sources BOSTON, Aug. 10 /PRNewswire/ -- ViaCell, Inc., a fully-integrated cellular therapy company committed to enabling the development of additional therapeutic applications for umbilical cord blood stem cells, commended...

Novazyme Pharmaceuticals Welcomes Key Manufacturing Appointments.
William J. Fallon Named Vice President, Technical Operations PRINCETON, N.J., May 23 /PRNewswire/ -- Novazyme Pharmaceuticals, Inc. today announced the appointment of William J. Fallon, as Vice President of Technical Operations. Mr. Fallon comes to Novazyme after serving as Vice President of Manufacturing at Transkaryotic...

Genzyme to Acquire Novazyme Pharmaceuticals.
Proprietary Glycoprotein Technology Platform Will Advance Lysosomal Storage Disorder Programs CAMBRIDGE, Mass., and PRINCETON, N.J., Aug. 7 /PRNewswire/ -- Genzyme Corp. and privately held Novazyme Pharmaceuticals Inc. today announced a definitive merger agreement under which Novazyme will be acquired by Genzyme and operate...

Novazyme Pharmaceuticals Raises $16.0 Million Through Private Equity Placement.
OKLAHOMA CITY, April 18 /PRNewswire Interactive News Release/ -- Novazyme Pharmaceuticals, Inc. today announced that the Company has completed a $16.0 million equity financing through the private placement of Series B preferred stock with a select group of investors. Investors participating in the financing include the Perseus-Soros...

TKT Awarded Broad Patent Relating to Production and Delivery of Proteins.
-- Further Strengthens Technological Base -- CAMBRIDGE, Mass., Aug. 14 /PRNewswire/ -- Transkaryotic Therapies, Inc. (Nasdaq: TKTX) today announced the U.S. Patent and Trademark Office has issued Patent No. 6,270,989 entitled, "Protein Production and Delivery." The patent relates to TKT's core technological base that is...